Combining PI3K, CDK4/6 pathway inhibitors and immunotherapies in triple-negative breast cancer (TNBC): a novel therapy combination

点击翻译按钮获取中文摘要

Triple-negative breast cancer (TNBC) has the worst prognosis of all breast cancer subtypes, classically affecting young women and characterized by a lack of effective therapies. We show that blocking both PI3K and CDK4/6 pathways together effectively reduces TNBC growth in mice and can enhance anti-tumour immune responses. We aim to understand how these drugs work together and if adding immunotherapy can improve responses. Our project could provide a new treatment approach for TNBC patients.